Welcome to our dedicated page for Claritev SEC filings (Ticker: CTEV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Claritev Corporation filings document a healthcare technology, data and insights issuer with Class A common stock listed on the NYSE under CTEV. Its Form 8-K reports furnish operating results, financial-condition updates, investor presentations and Regulation FD materials tied to its analytics, AI and claims-based healthcare cost-management platform.
Proxy and annual-meeting filings cover board elections, auditor ratification, executive compensation, stockholder votes and amendments to the Claritev Corporation 2020 Omnibus Incentive Plan. Other material-event reports address share-repurchase authorization, capital-structure matters and governance transitions.
Claritev Corp EVP and Chief Digital Officer Kim Michael reported an open-market purchase of 3,000 shares of Class A common stock at $16.65 per share. Following this transaction, Michael directly owns 185,878 shares, indicating a modest increase in personal equity exposure to Claritev.
Claritev Corp director Prince John Michael made an open‑market purchase of 10,000 shares of Class A common stock at $16.00 per share. Following this transaction, he now directly owns 31,662 shares of Claritev common stock.
Claritev Corp director, president, CEO and executive chair Dalton Travis reported open-market purchases of a total of 20,920 shares of Class A common stock on May 18, 2026. The transactions were made indirectly through his spouse’s Individual Retirement Account at weighted average prices in the low-$12 range.
Claritev Corporation furnished this report to address a media article about government scrutiny. The company explains that in August 2024 it received a confidential grand jury subpoena from the Antitrust Division of the Department of Justice in connection with an investigation regarding health insurance and has been cooperating fully. Claritev states that, over the subsequent two years, the DOJ has not informed the company that it is a target of the investigation. Management says it remains focused on working with healthcare clients and partners to improve transparency, access, and affordability, and includes standard cautionary language about forward-looking statements and legal risks.
Claritev Corporation reported mixed first-quarter 2026 results with modest growth but continued losses and heavy leverage. Revenues reached $244.7 million, up 5.8% from $231.3 million a year earlier, while Adjusted EBITDA rose 3.4% to $146.9 million, implying a 60.0% margin versus 61.4% in 2025.
The company posted a net loss of $73.6 million, slightly larger than the $71.3 million loss a year earlier, and net loss per share was $4.41. Operating cash flow was negative at $45.8 million and Free Cash Flow was a negative $92.5 million, reflecting high capital expenditures and interest costs.
Claritev ended the quarter with $21.3 million of unrestricted cash and total assets of about $4.84 billion against total liabilities of about $5.07 billion, resulting in a shareholders’ deficit. Management nudged full-year 2026 revenue guidance up to a range of $985 million to $1.0 billion, while keeping Adjusted EBITDA, capital expenditure, tax rate, and Free Cash Flow guidance unchanged.
Klapstein Julie D reported acquisition or exercise transactions in this Form 4 filing.
Claritev Corp director Julie D. Klapstein received a grant of 8,977 shares of Class A common stock in the form of restricted stock units. The award was granted at no cash cost per share and increases her direct holdings to 24,611 shares.
The restricted stock units vest on the earlier of one year from the grant date or the next regularly scheduled annual stockholder meeting, provided she continues serving through that date. If she resigns voluntarily without cause before then, the units vest on a pro rata basis according to days of service.
Klein Michael Stuart reported acquisition or exercise transactions in this Form 4 filing.
Claritev Corp director Michael Stuart Klein reported an equity award and updated share holdings. He received 8,977 shares of Class A common stock as restricted stock units at $0.00 per share, bringing his direct holdings to 24,334 shares.
The restricted stock units vest on the earlier of the one-year anniversary of the grant date or the next regularly scheduled annual stockholder meeting, subject to continued service, with pro rata vesting in certain voluntary resignation scenarios. The filing also reports 195,490 Class A shares held indirectly by M. Klein Associates, Inc. and another entity for which he serves as managing member. Klein is the controlling stockholder of M. Klein Associates, Inc. and disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Clarke Richard A reported acquisition or exercise transactions in this Form 4 filing.
Claritev Corp director Clarke Richard A reported receiving a grant of 8,977 shares of Class A common stock in the form of restricted stock units at a price of $0.00 per share. Following this equity award, he directly holds 24,334 shares.
The restricted stock units vest on the earlier of the one-year anniversary of the grant date or the issuer’s next regularly scheduled annual stockholder meeting, subject to continued service. If he voluntarily resigns when there are no grounds for termination for cause, the units vest on a pro rata basis according to days of service.
Kap Jason Lamar reported acquisition or exercise transactions in this Form 4 filing.
Claritev Corp director Jason Lamar Kap received an award of 8,977 shares of Class A common stock as restricted stock units. These units vest on the earlier of one year from the grant date or the next annual stockholder meeting, subject to continued service.
Following this grant, he directly holds 16,333 shares. If he voluntarily resigns (other than for cause), the restricted stock units vest on a pro rata basis according to days of service provided before departure.